HC Wainwright Comments on Scholar Rock Q3 Earnings

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Analysts at HC Wainwright issued their Q3 2025 EPS estimates for Scholar Rock in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.68) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for Scholar Rock's Q4 2025 earnings at ($0.62) EPS.

A number of other analysts have also recently commented on the stock. BMO Capital Markets boosted their target price on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an "outperform" rating in a research note on Friday, October 11th. Wedbush reaffirmed an "outperform" rating and set a $37.00 price objective on shares of Scholar Rock in a research note on Monday, November 4th. JPMorgan Chase & Co. upped their price objective on shares of Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a research note on Monday, October 14th. Finally, Piper Sandler upped their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $34.00.

Scholar Rock Stock Performance

SRRK traded up $0.12 on Thursday, reaching $27.50. The stock had a trading volume of 883,812 shares, compared to its average volume of 1,134,421. The company has a market cap of $2.20 billion, a P/E ratio of -11.65 and a beta of 0.47. The business's 50-day moving average price is $19.86 and its two-hundred day moving average price is $13.43. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock has a 12-month low of $6.76 and a 12-month high of $35.38.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently bought and sold shares of SRRK. Mirae Asset Global Investments Co. Ltd. grew its position in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock worth $25,000 after purchasing an additional 514 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Scholar Rock in the second quarter valued at about $98,000. Hsbc Holdings PLC purchased a new stake in shares of Scholar Rock in the second quarter valued at about $100,000. Point72 DIFC Ltd purchased a new stake in shares of Scholar Rock in the second quarter valued at about $103,000. Finally, Creative Planning purchased a new stake in shares of Scholar Rock in the third quarter valued at about $115,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Scholar Rock

In related news, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the completion of the transaction, the chief financial officer now owns 161,088 shares of the company's stock, valued at approximately $4,278,497.28. This trade represents a 56.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the sale, the director now owns 5,612,896 shares in the company, valued at approximately $164,177,208. This trade represents a 17.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,415,340 shares of company stock worth $40,666,088 in the last ninety days. 19.20% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.